Indaptus Therapeutics Inc
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Indaptus Therapeutics Inc is positioned to revolutionize the treatment of cancer and certain infectious diseases. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Latest INDP News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News